ELUTIA INC (ELUT) Stock Price, Quote, News and Overview
NASDAQ:ELUT - Nasdaq - US05479K1060 - Common Stock - Currency: USD
ELUT Quote, Performance and Key Statistics
1.81
+0.02 (+1.12%)
The current stock price of ELUT is 1.81 USD. In the past month the price increased by 4.02%. In the past year, price decreased by -48.29%.
ELUT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.04 | 327.31B | ||
| AMGN | AMGEN INC | 13.94 | 155.58B | ||
| GILD | GILEAD SCIENCES INC | 14.02 | 134.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.5 | 55.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.38B | ||
| ARGX | ARGENX SE - ADR | 94.29 | 33.10B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.32 | 26.73B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.61B | ||
| NTRA | NATERA INC | N/A | 23.47B | ||
| INSM | INSMED INC | N/A | 18.70B | ||
| BIIB | BIOGEN INC | 8.03 | 18.62B |
Related stock screener links
About ELUT
Company Profile
Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. The company is headquartered in Silver Spring, Maryland and currently employs 51 full-time employees. The company went IPO on 2020-10-08. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
Company Info
ELUTIA INC
12510 Prosperity Drive, Suite 370
Silver Spring MARYLAND US
Employees: 51
Phone: 12402471143
ELUTIA INC / ELUT FAQ
What is the stock price of ELUTIA INC today?
The current stock price of ELUT is 1.81 USD. The price increased by 1.12% in the last trading session.
What is the ticker symbol for ELUTIA INC stock?
The exchange symbol of ELUTIA INC is ELUT and it is listed on the Nasdaq exchange.
On which exchange is ELUT stock listed?
ELUT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ELUTIA INC stock?
8 analysts have analysed ELUT and the average price target is 7.65 USD. This implies a price increase of 322.65% is expected in the next year compared to the current price of 1.81. Check the ELUTIA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ELUTIA INC worth?
ELUTIA INC (ELUT) has a market capitalization of 74.43M USD. This makes ELUT a Micro Cap stock.
How many employees does ELUTIA INC have?
ELUTIA INC (ELUT) currently has 51 employees.
What are the support and resistance levels for ELUTIA INC (ELUT) stock?
ELUTIA INC (ELUT) has a support level at 1.79 and a resistance level at 1.86. Check the full technical report for a detailed analysis of ELUT support and resistance levels.
Is ELUTIA INC (ELUT) expected to grow?
The Revenue of ELUTIA INC (ELUT) is expected to grow by 15.73% in the next year. Check the estimates tab for more information on the ELUT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ELUTIA INC (ELUT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ELUT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ELUT, evaluating the profitability, health, valuation and growth aspects
- ELUTIA INC (ELUT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ELUTIA INC (ELUT) Sales and EPS estimates to see what analysts future expectations are.
- ELUTIA INC (ELUT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ELUTIA INC (ELUT) Insider and Institutional Ownership to learn about the owners and their transactions.
- ELUTIA INC (ELUT) Stock Chart to make your own analysis
- ELUTIA INC (ELUT) Latest news and press-releases to stay up to date.
Does ELUTIA INC (ELUT) stock pay dividends?
ELUT does not pay a dividend.
When does ELUTIA INC (ELUT) report earnings?
ELUTIA INC (ELUT) will report earnings on 2025-07-28.
What is the Price/Earnings (PE) ratio of ELUTIA INC (ELUT)?
ELUTIA INC (ELUT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.82).
What is the Short Interest ratio of ELUTIA INC (ELUT) stock?
The outstanding short interest for ELUTIA INC (ELUT) is 0.3% of its float. Check the ownership tab for more information on the ELUT short interest.
ELUT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ELUT. When comparing the yearly performance of all stocks, ELUT is a bad performer in the overall market: 94.52% of all stocks are doing better.
ELUT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ELUT. ELUT has a bad profitability rating. Also its financial health evaluation is rather negative.
ELUT Financial Highlights
Over the last trailing twelve months ELUT reported a non-GAAP Earnings per Share(EPS) of -1.82. The EPS increased by 23.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -147.29% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ELUT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ELUT. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 73.57% and a revenue growth 15.73% for ELUT